Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease: Figure 1

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action

(2013) Hanna Iderberg et al.   EXPERIMENTAL NEUROLOGY

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease

(2013) Pierre Paoletti et al.   NATURE REVIEWS NEUROSCIENCE

Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease

(2012) M. A. Cenci et al.   CNS & Neurological Disorders-Drug Targets

Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease

(2012) K. Elisabet Ohlin et al.   NEUROIMAGE

Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia

(2012) Khaled-Ezaheir Bennouar et al.   NEUROPHARMACOLOGY

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats

(2011) Kristin B. Dupre et al.   EXPERIMENTAL NEUROLOGY

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease

(2011) Christopher Kobylecki et al.   MOVEMENT DISORDERS

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels

(2011) Flora Mela et al.   NEUROBIOLOGY OF DISEASE

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

(2011) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease

(2011) Véronique Sgambato-Faure et al.   PROGRESS IN NEUROBIOLOGY

Integrated Brain Circuits: Astrocytic Networks Modulate Neuronal Activity and Behavior

(2010) Michael M. Halassa et al.   Annual Review of Physiology

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease

(2010) Christopher Kobylecki et al.   JOURNAL OF NEUROCHEMISTRY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

(2010) S. Fasano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Astrocytes and the regulation of cerebral blood flow

(2009) Raymond C. Koehler et al.   TRENDS IN NEUROSCIENCES

Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease

(2008) S. Hirano et al.   JOURNAL OF NEUROSCIENCE

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

(2008) John G. Nutt et al.   MOVEMENT DISORDERS

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

(2007) Barbara Picconi et al.   NEUROBIOLOGY OF DISEASE